Rare diseases specialist Swedish Orphan Biovitrum (Sobi) has agreed to buy the drug emapalumab and is reorganizing to increase focus on late-stage development in hematology and immunology.
The drugmaker said on Wednesday it would buy a newly established company owning the drug candidate for the treatment of primary haemophagocytic lymphohistiocytosis (HLH), and related assets, for 4.9 billion crowns ($519 mln).
HTH is a rare life-threatening condition in which the immune system attacks tissues and organs, mainly in young children.
Sobi signed an exclusive license agreement in 2018 with Swiss company Novimmune for the rights to emapalumab, with an option to buy all assets at a later stage.
Sobi said the refocusing of its research and development operations, at a cost of 100–200 million crowns in 2019, would lead to annual savings of 200–300 million from 2020 that would allow it to invest more in late-stage development projects.
“This planned structural alignment will sharpen the focus of the company on our two main areas: Hematology and Immunology. The integration of the emapalumab organization makes this alignment possible,” CEO Guido Oelkers said.
The rival to Roche, Novo Nordisk and Shire said it expected the acquisition, which is debt financed, to be earnings neutral in 2019.
It stuck to its target for a full-year profit before amortization of 5.0-5.3 billion crowns on sales of 12.5-13.0 billion.
By Anna Ringstrom
Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has provided a positive opinion for the company’s Sogroya therapy. The once-weekly treatment – also known as somapacitan – is for the replacement of endogenous growth hormone (GH) in aged children three years and older.
Medtronic is set to acquire EOFlow, the South Korea-based maker of an insulin patch pump. In its announcement of the deal Thursday, Medtronic suggested that integrating the tubeless device with its own continuous glucose monitors and meal-detection algorithm could create a new closed-loop system for largely hands-off diabetes management.
Apnimed started the year by bagging nearly $80 million in extended series C funds and the momentum has kept up, with the sleep-apnea-focused biotech nailing its goals in a phase 2 study. “For those who cannot tolerate current treatments, AD109 has the potential to be a convenient, oral pill that could improve people’s quality of life both at night and during the day.”